December 23, 2015 |
Good news for Gilead Sciences ($GILD) and Bristol-Myers Squibb ($BMY): Australia's federal government wants to eliminate hepatitis C in the country. And it plans to shell out $1 billion on the drugmakers' meds to do that.
Wednesday, December 23, 2015
Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease
Australia bets $1B on pricey hep C drugs in broad effort to eradicate the disease
Australia is earmarking $1 billion to subsidize Gilead's Sovaldi and Harvoni, along with Bristol's Daklinza--as well as Pendopharm's ribavirin tablets, Ibavyr--for all hep C patients, regardless of their age or how they acquired the disease, Sky News reports. Authorities are hoping the investment can wipe the malady off the continental map within 20 years.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment